Sonja A Swanson1, Sonia Hernandez-Diaz1, Kristin Palmsten2, Helen Mogun3, Mark Olfson4, Krista F Huybrechts3. 1. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA. 2. Department of Pediatrics, University of California, San Diego. 3. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School. 4. New York State Psychiatric Institute, New York; the Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York.
Abstract
PURPOSE: The decision whether to continue antidepressant use for depression during pregnancy requires weighing maternal and child risks and benefits. Little is known about the effectiveness of antidepressant therapy during pregnancy. The goal of this study is to evaluate whether standard administrative claims data can be used to evaluate the effectiveness of antidepressants. METHODS: Using prescription and healthcare visit Medicaid claims (2000-2007), we identified 28 493 women with a depression diagnosis and antidepressant fill in the 90 days before their last menstrual period. Antidepressant continuation was defined based on prescription fills during the first trimester. Depression hospitalizations and deliberate self-harm served as measures of the effectiveness of treatment continuation during pregnancy. Propensity score and instrumental variable analyses were used to attempt to account for confounding. RESULTS: Relative to women who discontinued antidepressant therapy, women who continued were more likely to have a depression inpatient stay (odds ratio [OR] = 2.2, 95% confidence interval [95%CI]: 2.0-2.4) and deliberate self-harm code (OR = 1.4, 95%CI: 0.7-2.7). Accounting for measured covariates in the propensity score analysis, including age, race, comorbidities, comedications, features of the depression diagnosis, and antidepressant class, led to slightly attenuated estimates (OR = 2.0, 95%CI: 1.8-2.2; OR = 1.1, 95%CI: 0.5-2.4). Similar associations were estimated in subgroups with different levels of baseline depression severity. Proposed preference-time, calendar-time-based, and geography-based instruments were unlikely to meet the required conditions for a valid analysis. CONCLUSIONS: Our findings suggest that either antidepressant medications do not reduce the risk of depression relapse in pregnant women, or that administrative data alone could not be used to validly estimate the effectiveness of psychotropic medications during pregnancy.
PURPOSE: The decision whether to continue antidepressant use for depression during pregnancy requires weighing maternal and child risks and benefits. Little is known about the effectiveness of antidepressant therapy during pregnancy. The goal of this study is to evaluate whether standard administrative claims data can be used to evaluate the effectiveness of antidepressants. METHODS: Using prescription and healthcare visit Medicaid claims (2000-2007), we identified 28 493 women with a depression diagnosis and antidepressant fill in the 90 days before their last menstrual period. Antidepressant continuation was defined based on prescription fills during the first trimester. Depression hospitalizations and deliberate self-harm served as measures of the effectiveness of treatment continuation during pregnancy. Propensity score and instrumental variable analyses were used to attempt to account for confounding. RESULTS: Relative to women who discontinued antidepressant therapy, women who continued were more likely to have a depression inpatient stay (odds ratio [OR] = 2.2, 95% confidence interval [95%CI]: 2.0-2.4) and deliberate self-harm code (OR = 1.4, 95%CI: 0.7-2.7). Accounting for measured covariates in the propensity score analysis, including age, race, comorbidities, comedications, features of the depression diagnosis, and antidepressant class, led to slightly attenuated estimates (OR = 2.0, 95%CI: 1.8-2.2; OR = 1.1, 95%CI: 0.5-2.4). Similar associations were estimated in subgroups with different levels of baseline depression severity. Proposed preference-time, calendar-time-based, and geography-based instruments were unlikely to meet the required conditions for a valid analysis. CONCLUSIONS: Our findings suggest that either antidepressant medications do not reduce the risk of depression relapse in pregnant women, or that administrative data alone could not be used to validly estimate the effectiveness of psychotropic medications during pregnancy.
Authors: Alan F Schatzberg; Pierre Blier; Pedro L Delgado; Maurizio Fava; Peter M Haddad; Richard C Shelton Journal: J Clin Psychiatry Date: 2006 Impact factor: 4.384
Authors: Dorothy Sit; James M Perel; James F Luther; Stephen R Wisniewski; Joseph C Helsel; Katherine L Wisner Journal: J Clin Psychopharmacol Date: 2010-08 Impact factor: 3.153
Authors: Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett Journal: JAMA Date: 2010-01-06 Impact factor: 56.272
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Casey R Tak; Kathleen M Job; Katie Schoen-Gentry; Sarah C Campbell; Patrick Carroll; Maged Costantine; Diana Brixner; Angela K Birnbaum; Catherine M T Sherwin Journal: Eur J Clin Pharmacol Date: 2017-06-09 Impact factor: 2.953
Authors: Ellen C Caniglia; L Paloma Rojas-Saunero; Saima Hilal; Silvan Licher; Roger Logan; Bruno Stricker; M Arfan Ikram; Sonja A Swanson Journal: Neurology Date: 2020-08-04 Impact factor: 9.910
Authors: Anick Bérard; Andrea Gaedigk; Odile Sheehy; Christina Chambers; Mark Roth; Pina Bozzo; Diana Johnson; Kelly Kao; Sharon Lavigne; Lori Wolfe; Dee Quinn; Kristen Dieter; Jin-Ping Zhao Journal: Front Pharmacol Date: 2017-07-17 Impact factor: 5.810